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Abstract
Background: Frontotemporal lobar degeneration (FTLD) is a progressive neurodegenerative disorder that can be
triggered through genetic or sporadic mechanisms. MicroRNAs (miRNAs) have become a major therapeutic focus
as their pervasive expression and powerful regulatory roles in disease pathogenesis become increasingly apparent.
Here we examine the role of miRNAs in FTLD patients with TAR DNA-binding protein 43 pathology (FTLD-TDP)
caused by genetic mutations in the progranulin (PGRN) gene.
Results: Using miRNA array profiling, we identified the 20 miRNAs that showed greatest evidence (unadjusted P <
0.05) of dysregulation in frontal cortex of eight FTLD-TDP patients carrying PGRN mutations when compared to 32
FTLD-TDP patients with no apparent genetic abnormalities. Quantitative real-time PCR (qRT-PCR) analyses provided
technical validation of the differential expression for 9 of the 20 miRNAs in frontal cortex. Additional qRT-PCR
analyses showed that 5 out of 9 miRNAs (miR-922, miR-516a-3p, miR-571, miR-548b-5p, and miR-548c-5p) were also
significantly dysregulated (unadjusted P < 0.05) in cerebellar tissue samples of PGRN mutation carriers, consistent
with a systemic reduction in PGRN levels. We developed a list of gene targets for the 5 candidate miRNAs and
found 18 genes dysregulated in a reported FTLD mRNA study to exhibit anti-correlated miRNA-mRNA patterns in
affected cortex and cerebellar tissue. Among the targets is brain-specific angiogenesis inhibitor 3, which was
recently identified as an important player in synapse biology.
Conclusions: Our study suggests that miRNAs may contribute to the pathogenesis of FTLD-TDP caused by PGRN
mutations and provides new insight into potential future therapeutic options.
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Background
Frontotemporal lobar degeneration (FTLD) is the sec-
ond most common cause of early-onset dementia after
Alzheimer’s Disease (AD) [1]. FTLD patients are clini-
cally characterized by personality changes and disinhib-
ited behaviour, often combined with a gradual and
progressive language dysfunction [2]. Memory impair-
ment is typically preserved in the early phase of disease,
which distinguishes them from patients with AD. Patho-
logically, around 40% of FTLD patients present with
neuronal and/or glial tau aggregates (FTLD-tau),
whereas the majority of FTLD patients show ubiquitin-
immunoreactive cytoplasmic and intranuclear inclusions
historically referred to as FTLD-U (FTLD with ubiqui-
tin-positive inclusions) [3]. More recently, it was shown
that hyperphosphorylated and C-terminal truncated
fragments of the nuclear protein TAR DNA-binding
protein 43 (TDP-43) were the main component of the
pathological inclusions in FTLD-U, and the term FTLD-
TDP was introduced [4,5]. Three main patterns of TDP-
43 pathology are recognized in FTLD-TDP, based on
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the anatomical distribution, morphology, and relative
proportion of distinct types of inclusions [6,7]. In this
study, we will follow the nomenclature based on the
Mackenzie scheme [6] where FTLD-TDP type 1 is char-
acterized by TDP-43 positive compact neuronal cyto-
plasmic inclusions and short neurites, FTLD-TDP type 2
presents with long TDP-43 positive neurites and FTLD-
TDP type 3 is characterized by compact and granular
cytoplasmic inclusions.
In the past decade, several different genes and chro-
mosomal loci have been associated with FTLD. Muta-
tions in the microtubule associated protein tau (MAPT)
gene were first identified as a cause of familial FTLD-
tau [8-10]. More recently, our group and others discov-
ered that heterozygous mutations in the progranulin
gene (PGRN) cause FTLD-TDP through a loss of func-
tion mechanism [11,12]. Patients with PGRN mutations
maintain only a single functional copy of the gene, lead-
ing to the loss of 50% of functional PGRN, causing dis-
ease through haploinsufficiency. The reduced level of
PGRN, a growth factor with a key role in a variety of
cellular responses, provokes neurodegeneration and
associated symptomatology in FTLD patients, including
deficits in behaviour, language, and movement [13-15].
Interestingly, all patients with PGRN mutations present
with FTLD-TDP pathology type 1 [16,17]; however,
FTLD-TDP Type 1 is also observed in a subset of
FTLD-TDP patients without PGRN mutations. Although
there are clear pathologic distinctions in FTLD-TDP,
the molecular pathways which underlie its progression
are still mostly undefined. Recent advances in our
understanding of the mammalian genomes, however,
have revealed novel regulatory mechanisms with critical
roles in disease pathogenesis, thus offering new avenues
to explore.
The recent discovery of pervasive expression for non-
coding RNAs (ncRNAs) in our genomes through exten-
sive ‘transcriptomic’ efforts [18-23] has significantly
enhanced our fundamental knowledge of cellular signal-
ing cascades and will likely reshape future drug discov-
ery efforts. Indeed, PGRN mutation carriers diagnosed
with FTLD exhibit a range of pathologic and phenotypic
outcomes, suggesting that other contributing factors,
such as ncRNAs, mediate disease progression [4,11,12,
15,19,24].
The miRNA class of ncRNA, in particular, has gener-
ated a lot of interest as their widespread role in many
cellular functions becomes increasingly apparent
[18,25-31]. One miRNA can control the expression of
hundreds of downstream gene targets, underscoring the
importance of characterizing their functional roles in
vitro and in vivo [25]. Over the last few years, a growing
number of publications have reported dysregulation of
miRNA expression in numerous diseases, including
neurodegenerative disorders, such as Alzheimer’s disease
and Huntington’s disease [28,32-34]. Recent reports
have also examined miRNA regulation of PGRN, sug-
gesting that this gene is under the control of ncRNAs,
including miR-107, and miR-29b [35,36]. Furthermore,
our group previously showed a functional disruption of
a miR-659 binding site in FTLD patients with a com-
mon genetic variant of PGRN (rs5848) [37].
Here we profiled miRNA expression in the frontal
cortex of a population of FTLD-TDP patients with
PGRN mutations and compared their miRNA expres-
sion pattern with a large group of FTLD-TDP patients
without PGRN mutations, with the goal to identify miR-
NAs responsive to PGRN haploinsufficiency. For those
miRNAs showing greatest evidence of dysregulation and
that were validated technically by quantitative real-time
PCR in frontal cortex, we further examined their
expression in the cerebellum, with the expectation that
PGRN levels are globally disrupted throughout the
CNS. Finally, we developed a unique list of gene targets
predicted to be regulated by miRNAs dysregulated in
both frontal cortex and cerebellum in our patient sam-
ples, based on previously reported microarray mRNA
data as well as bioinformatic miRNA target prediction
sites.
Results
miRNA array results from frontal cortex
Using the ABI v2.0 arrays, we profiled the expression of
664 miRNAs from 40 FTLD-TDP patients, including 32
PGRN- FTLD-TDP and 8 PGRN+ FTLD-TDP patients
(patient demographics listed in Table 1). There was
detectable expression for 490 of the 664 miRNAs present
on the array, and those candidate miRNAs were sub-
jected to further analysis. We identified the 20 miRNAs
which showed greatest evidence of differential expression
(those with unadjusted P < 0.05) between the PGRN+
and PGRN- FTLD-TDP groups (Figure 1). None of these
were statistically significant after accounting for multiple
testing (overall P = 0.34) and the smallest q-value was
0.57, however we still pursued these 20 top-ranking miR-
NAs as the most promising candidates. Ten out of the 20
miRNAs had higher expression in the PGRN+ FTLD-
TDP group (miR-571, miR548c-5p, miR-572, miR-922,
miR-516a-3p, miR-566, miR-597, miR-645, miR-548b-5p,
miR330-5p), while the other 10 miRNAs had lower
expression in this group (miR-33a*, miR639, miR-630,
miR-887, miR-565, miR-192*, miR-618, miR-24-1*, let-
7d*, and let-7i*). All miRNA array results and statistical
analyses are listed in Additional File 1. Graphical display
of the 20 significantly changed miRNAs showed a consis-
tent miRNA expression pattern in all three PGRN-
FTLD-TDP subtypes (type 1, 2 and 3) compared to
PGRN+ FTLD-TDP (Additional File 2).
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miRNA validation from frontal cortex
To perform technical validation of the miRNA array
results, we evaluated the expression of the 20 significantly
dysregulated miRNAs between the PGRN+ and PGRN-
FTLD-TDP patients by qRT-PCR. One miRNA, miR-645,
was undetectable using the individual miRNA assays
from ABI. Of the remaining 19 detectable miRNAs, nine
could be confirmed by qRT-PCR as significantly altered
between the PGRN+ and PGRN- FTLD-TDP groups with
P < 0.05. The validated miRNAs were miR-565, miR-
33a*, let7i*, miR-922, miR-571, miR-572, miR-548b-5p,
miR-548c-5p and miR-516a-3p (Figure 2).
miRNA validation from cerebellum
We hypothesized that the miRNAs dysregulated in the
frontal cortex of the PGRN+ FTLD-TDP patients could
also be differentially expressed in other brain areas as
haploinsufficiency of PGRN function would not be
region-specific. We therefore selected the 8 frontal cortex
validated miRNAs with the largest estimated fold change
and profiled their expression in the cerebellum of 10
PGRN+ FTLD-TDP and 30 PGRN- FTLD-TDP patients
(patient demographics listed in Table 1, 31 patients com-
mon to frontal cortex analyses). Five of the 9 miRNAs
(miR-922, miR-516a-3p, miR-571, miR-548b-5p, and
Table 1 Patient demographics for frontal cortex and cerebellar brain samples included in this study
Mutation status N FTLD-TDP Type 1 FTLD-TDP Type 2 FTLD-TDP Type 3 Male/Female Mean age at death ± SD
PGRN + Cortex 8 8 n/a n/a 3/5 75.5 ± 10.1 (63-87)
PGRN -
Cortex
32 12 11 9 18/14 74.9 ± 10.5 (52-97)
PGRN +
Cerebellum
10 10 n/a n/a 7/3 72.3 ± 10.3 (56-87)
PGRN -
Cerebellum
30 12 12 6 16/14 73.8 ± 10.3 (52-97)
* There was overlap of 6 PGRN+ and 25 PGRN- samples between the cerebellum and frontal cortex analyses. n/a = not applicable
Figure 1 Cluster diagram of Ct values for the 20 significant miRNAs from the array profiling. Each column represents a single sample,
and each row represents a single miRNA. Green squares represent lower than median level of miRNA expression; black squares represent
median level of miRNA expression; red squares represent higher than median level of miRNA expression. Legend units: 1.0 = differs from median
probe intensity by one Ct unit. In addition to PGRN+ and PGRN- FTLD-TDP patients, 3 different FTLD-TDP pathologic subtypes are represented in
this heat map: PGRN+ FTLD-TDP type 1 and PGRN- FTLD-TDP types 1, 2, and 3.
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miR-548c-5p), were significantly altered with P < 0.05 in
the cerebellum (Figure 3).
miRNA expression in vitro
To further study the relationship between the loss of
PGRN and the top five dysregulated miRNAs identified
in frontal cortex and cerebellum, we performed a preli-
minary in vitro study in human neuroblastoma SH-SY5Y
cells. In cells treated with PGRN siRNA we detected a
60% decrease in PGRN mRNA levels compared to nega-
tive control siRNA treated cells; however, no difference
in miRNA expression for miR-516a-3p, miR-548b-5p and
miR-548c-5p was observed (Additional File 3). Expres-
sion of miR-571 and miR-922 was too low (Ct < 35) and
could not be included in the analysis.
TargetScan analysis and Ingenuity pathway analysis of
miRNA targets
The overall role of miRNAs is to repress mRNA and pro-
tein expression [25,38]. To facilitate the identification of
mRNA targets for the 5 PGRN+ FTLD-TDP associated
miRNAs, we made use of publicly available Affymetrix
mRNA arrays performed in FTLD-TDP patients with and
without PGRN mutations (GEO record GDS3459) [39].
Since all 5 miRNAs were upregulated in frontal cortex
and cerebellum of PGRN mutation carriers, we focused
on mRNA targets which were downregulated in both
frontal cortex and cerebellum of PGRN mutations car-
riers in the Affymetrix mRNA arrays. A total of 177 pro-
besets showed significant downregulated expression in
both the cortex and cerebellum of the PGRN+ FTLD-
TDP patients (P < 0.05). When compared with the list of
TargetScan predicted genes for each of the 5 PGRN+
FTLD-TDP associated miRNAs, 18 genes with anti-
correlated mRNA-miRNA expression were identified
(Table 2). Among the 18 genes, brain-specific angiogen-
esis inhibitor 3 (BAI3), glycerol kinase (GK) and solute
carrier family 23, member 2 (SLC23A2) were targeted by
3 of the 5 miRNAs upregulated in the cortex and cerebel-
lum of the PGRN+ FTLD-TDP patients. Seven genes
                                         
                              Fold Change in Frontal Cortex 
Figure 2 Validation of miRNA candidates in frontal cortex of FTLD patients. For each miRNA, fold change of PGRN+ FTLD-TDP patients
compared to PGRN- FTLD-TDP patients with 95% confidence intervals are shown with their associated p-value. Significantly dysregulated miRNAs
are shown in bold. Solid bars represent miRNAs which were upregulated in the original miRNA array, dashed bars represent miRNAs
downregulated in the original miRNA array.
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were targeted by 2 of the 5 miRNAs, and 8 genes were
targeted by 1 of the 5 miRNAs (Table 2).
Next, for the 18 genes we found in common between
the TargetScan and Affymetrix results, we examined
their potential biological roles with Ingenuity Pathway
analysis. Interestingly, neurological and cellular regula-
tions were the most prominently represented biological
roles of the significant pathways identified (P value <
0.05). In fact, 6 of the genes (astrotactin 1 (ASTN1), pro-
tein tyrosine phosphatase, receptor type, D (PTPRD),
         Fold Change in Cerebellum 
Figure 3 Validation of miRNA candidates in cerebellum of FTLD patients. For each miRNA, fold change of PGRN+ FTLD-TDP patients
compared to PGRN- FTLD-TDP patients with 95% confidence intervals are shown with their associated p-value. Significantly dysregulated miRNAs
are shown in bold. Solid bars represent miRNAs which were upregulated in the frontal cortex, dashed bars represent miRNAs downregulated in
the frontal cortex.
Table 2 Candidate gene targets identified in this study
Gene Name miRNA species
BAI3 brain-specific angiogenesis inhibitor 3 miR-922; miR-548b-5p; miR-548c-5p
GK glycerol kinase miR-571; miR-548b-5p; miR-548c-5p
SLC23A2 solute carrier family 23 (nucleobase transporters), member 2 miR-922; miR-548b-5p; miR-548c-5p
GTDC1 glycosyltransferase-like domain containing 1 miR-516a-3p; miR-571
CNR1 cannabinoid receptor 1 miR-548b-5p; miR-548c-5p
FAM134B family with sequence similarity 134, member B miR-548b-5p; miR-548c-5p
HS2ST1 heparan sulfate 2-O-sulfotransferase 1 miR-548b-5p; miR-548c-5p
MYT1L myelin transcription factor 1-like miR-548b-5p; miR-548c-5p
NCAM1 neural cell adhesion molecule 1 miR-548b-5p; miR-548c-5p
TMEM135 transmembrane protein 135 miR-548b-5p; miR-548c-5p
ATP8A1 ATPase, class I, type 8A, member 1 miR-922
KCNAB1 potassium voltage-gated channel, shaker-related subfamily, beta member 1 miR-922
PTPRD protein tyrosine phosphatase, receptor type, D miR-922
RASA1 RAS p21 protein activator 1 miR-922
REEP1 receptor accessory protein 1 miR-922
SNCA synuclein, alpha miR-922
A2BP1 ataxin-2-binding protein 1 miR-516a-3p
ASTN1 astrotactin 1 miR-516a-3p
List of top scoring genes predicted to be regulated by the 5 significantly upregulated miRNAs (miR-922, miR-516a-3p, miR-571, miR-548b-5p, and miR-548c-5p)
from the 177 mRNAs significantly downregulated in frontal cortex and cerebellum in PGRN+ compared to PGRN- FTLD-TDP patients (GEO record GDS3459).
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potassium voltage-gated channel, shaker-related subfam-
ily, beta member 1 (KCNAB1), cannabinoid receptor 1
(CNR1), alpha-synuclein (SNCA), and neural cell adhe-
sion molecule 1 (NCAM1)) were shown to have a specific
role in behavioural responses, a phenotype which is con-
sistently altered in FTLD (Additional File 4).
Discussion
Identifying the molecular events leading to pathogenic
outcomes in neurodegenerative diseases, such as FTLD,
may ultimately produce new avenues for prevention or
treatment of these disorders. In this study, we report a
novel role for ncRNAs in the molecular profile of FTLD
patients with genetic mutations in the secreted growth
factor PGRN. The miRNA family of ncRNAs showed dis-
tinct expression patterns in post-mortem brain tissue of
FTLD-TDP patients carrying loss-of function mutations
in PGRN compared to FTLD-TDP patients without
known mutations, suggesting that miRNAs are potential
biomarkers and therapeutic targets for genetically-linked
dementia disorders.
Since the initial reports linking PGRN mutations to
FTLD [11,12], the search for PGRN mediated signaling
cascades has intensified, such as the recently reported
associations with sortilin (SORT1) [40,41]. Through the
comparison of ncRNA expression profiles from patients
with genetic versus non-genetic (or sporadic) diagnosis
of FTLD-TDP, we aimed to identify new pathways which
are under the control of PGRN signaling in vivo. Indeed,
in frontal cortex samples of FTLD-TDP patients, the
expression of 3% of the detectable miRNAs from the
expression arrays was significantly changed when PGRN+
and PGRN- FTLD-TDP patients were compared. More-
over, the dysregulated miRNAs showed consistent trends
in all three of the PGRN- FTLD-TDP subtypes (types 1-
3) compared to PGRN+ FTLD-TDP patients, suggesting
the miRNA candidates we identified are unique to PGRN
haploinsufficiency. In further support that the miRNAs
dysregulated in our array and validation studies are
under the control of systemic PGRN-mediated mechan-
isms, we found that 5 miRNAs (miR-548b-5p, miR-548c-
5p, miR-571, miR-922, and miR-516a-3p) were also upre-
gulated in the cerebellum of PGRN+ FTLD-TDP com-
pared to PGRN- FTLD-TDP patients.
To further study the five candidate miRNAs, we
silenced PGRN expression in SH-SY5Y cells; however,
none of the 3 miRNAs detectable in SY-SY5Y cells dis-
played a significant difference in expression between con-
trol and PGRN-silenced cells. This finding suggests that
long-term knockdown of PGRN may be necessary, con-
sistent with the late onset of symptoms in human FTLD
patients.
The mechanism by which PGRN haploinsufficiency in
FTLD patients leads to altered miRNA expression is
currently unclear and requires future studies. Progranu-
lin downstream signalling involves ERK1/2 and AKT
signalling and these are potential causes of altered
miRNA expression. It is unlikely that the five miRNAs
identified in this study are dysregulated as a result of
TDP-43 aggregation since the FTLD-TDP type 1 pathol-
ogy in the PGRN mutation carriers is indistinguishable
from the pathology observed in sporadic FTLD-TDP
patients.
It is now known that miRNAs can modulate mRNA
stability and translation [25,38], therefore, we correlated
publicly available mRNA expression results from spora-
dic (PGRN-) FTLD-TDP and PGRN+ FTLD-TDP
patients with bioinformatic miRNA target predictions
(TargetScan) for the 5 miRNAs upregulated in the frontal
cortex and cerebellum [39]. Through this analysis, we
identified 18 predicted gene targets with significantly
downregulated mRNA expression profiles in PGRN+
FTLD-TDP patients. The anti-correlated expression of
the upregulated miRNAs with their downregulated
mRNA targets in PGRN+ patients parallels the estab-
lished miRNA-mRNA regulatory relationship. Notably,
Ingenuity pathway analysis of the 18 genes revealed that
they have important links to biological functions involved
in FTLD disease pathogenesis, including nervous system
development, behavioural responses, and cell growth.
Indeed, ASTN1 is known to regulate neuronal migration
in cortical regions of developing brain [42], SNCA is
associated with neurodegeneration and dementias,
including links to FTLD-TDP in PGRN+ patients [43-46]
and REEP1 has been implicated in corticospinal neurode-
generative disorders [47]. Importantly, only 3 genes are
predicted to be targeted by 3 of the 5 miRNAs signifi-
cantly dysregulated in both frontal cortex and cerebel-
lum, including BAI3, a cell adhesion G protein coupled
receptor. This finding is of significant interest since Bolli-
ger et al. recently reported that C1q-like proteins can act
as secreted signalling molecules that bind to BAI3 leading
to the regulation of synapse formation and maintenance.
In support of their finding, both C1ql and BAI3 are
highly and specifically expressed in brain and are
enriched in neurons [48]. Based on these findings our
current data suggest that the loss of PGRN may increase
the expression of miR-922, miR-548b-5p and miR-548c-
5p through unknown mechanisms, leading to a decrease
in the levels of BAI3, an essential protein for synapse
biology.
Conclusions
Overall, our studies support a novel role for miRNAs in
FTLD-TDP due to PGRN dysfunction and emphasize the
value of combined miRNA and mRNA analyses. Future
experiments in cell and animal models are needed to
further evaluate the clinical potential of the miRNAs and
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gene targets identified in this study. The recent progress
in human trials for miRNA-based therapeutics in non-
CNS related disorders [49,50] offers hope for new alter-
natives for the treatment of dementias, including FTLD.
Methods
Brain samples
For the miRNA array experiment, post-mortem midfron-
tal cortex tissue was isolated from a collection of 40
FTLD-TDP patients selected from the Mayo Clinic Jack-
sonville (MCJ) brain bank. All samples were obtained
with appropriate informed consent with ethical commit-
tee approval. FTLD patients included the following
pathologic classifications: FTLD-TDP type 1 without
PGRN mutations (PGRN- type 1, N = 12), FTLD-TDP
type 2 (N = 11), FTLD-TDP type 3 (N = 9) and FTLD-
TDP type 1 with PGRN mutations (PGRN+ type I, N =
8). Total RNA quantification was performed using a
NanoDrop ND-1000 spectrophotometer (NanoDrop,
Wilmington, DE). RNA quality was evaluated by the Agi-
lent RNA 6000 Nano Kit (Agilent, Santa Clara, CA) and
only samples with an RNA integrity value greater than 5
were included in this study. Mean RINs in frontal cortex
were PGRN+ (5.6 ± 0.4), PGRN- type 1 (6.2 ± 0.6),
FTLD-TDP type 2 (6.2 ± 1.0), and FTLD-TDP type 3 (6.4
± 0.8). Mean RINs in cerebellums were PGRN+ (7.1 ±
0.6), PGRN- type 1 (7.0 ± 1.9), FTLD-TDP type 2 (7.2 ±
1.8), and FTLD-TDP type 3 (7.9 ± 0.4). Cerebellar tissue
of sufficient quality for miRNA expression analyses was
also available for 31 of these FTLD-TDP patients. For the
miRNA expression analyses in cerebellum, 9 additional
FTLD-TDP patients were obtained from the MCJ brain
bank. Importantly, all PGRN mutations included in this
study were clear pathogenic loss-of-function mutations,
leading to haploinsufficiency. Demographic and neuro-
pathologic information on all patients included in this
study are summarized in Table 1.
miRNA array analyses
For mature miRNA expression profiling, real-time RT-
PCR was performed using TaqMan Human MicroRNA
Low Density Arrays Version 2.0 (Applied Biosystems)
which contain 667 unique assays specific to human
mature miRNAs in a two-card format. Total RNA was
isolated from human frontal cortical tissue using the
miRVana PARIS kit from Ambion (Applied Biosystems).
Total RNA (150 ng) was reverse transcribed to cDNA for
mature miRNAs using Megaplex RT Primers (Applied
Biosystems) in 7.5 μls of final reaction volume. Subse-
quently, 2.5 μls of cDNA was pre-amplified in a 25 μl
final volume with PreAmp Master Mix and Megaplex
PreAmp Primers using standard conditions according to
manufacturer’s instructions. Preamplified cDNA was
diluted in 0.1× Tris-EDTA (pH 8.0), applied to miRNA
real-time array plates and mature miRNA expression was
assessed using Applied Biosystems 7900HT System.
Statistical analysis of miRNA array data
There were 664 miRNAs profiled for each of the 40 sam-
ples; Ct values were obtained with the automatic baseline
and manual Ct set to 0.1 threshold. Some miRNAs were
only minimally expressed, and were excluded from
further analyses; specifically we excluded those for which
20% or more of the samples had a missing Ct or Ct > 35.
Lowess smoothing was used to normalize measures
across individuals. Missing values were imputed using a
K-Nearest Neighbour approach as described by Tusher et
al. [51]. Any particularly extreme values for each miRNA
were ‘shrunk’ in towards the center of the distribution so
as to lessen their influence. For each comparison of two
groups, two sample t-tests were used to assess nominal
significance. The Westfall-Young min-P approach using
1000 permutations of group labels was used to obtain
p-values adjusted for multiple testing [52]. Empirical
q-values were also estimated using the permuted data.
Heat Maps and Box plots based on the miRNA array data
Normalized Ct values were adjusted by subtracting the
Ct value from an arbitrary constant value of 40 so that a
higher adjusted Ct value would correspond to a higher
miRNA expression. The table of adjusted Ct values for
the 20 significantly dysregulated miRNAs (P < 0.05)
between PGRN+ and PGRN- FTLD-TDP patients was
loaded in Cluster 3.0 [53]. A heat map showing the
miRNA expression profiles for all the samples was gen-
erated after median centering the adjusted Ct values for
each miRNA. The normalized and adjusted Ct values
were summarized across groups with boxplots.
Validation of miRNA candidates in frontal cortex and
cerebellum
The top 20 miRNA candidates identified in the miRNA
array experiment were selected for validation by qRT-
PCR in the same set of 8 PGRN+ and 32 PGRN- FTLD-
TDP patient samples. In brief, 50 μls of reverse transcrip-
tion primers (miRNA assay kits from ABI) for the 20
miRNAs plus RNU48 as an endogenous control were
divided into 3 primer pools, lyophilized, and subse-
quently resuspended in water for each pool resulting in
5× multiplex RT primer pool. Total RNA (200 ng) was
reverse transcribed in a 20-μl reaction volume using the
miRNA Reverse Transcription Kit (Applied Biosystems)
and 1 μl of cDNA was used in the Taqman miRNA
assays [19]. Where duplicate Ct values differed by more
than 2, the more extreme one relative to the distribution
of Ct values across all samples was deleted; otherwise the
mean of the duplicates was used as the final Ct for a tran-
script. Delta Cts were calculated by subtracting the Ct of
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the endogenous control RNU48. Minus delta Cts were
used as the final values for analysis and assumed to
represent the log base 2 of scaled expression levels. Two
sample t-tests and corresponding 95% confidence inter-
vals (CI) were used to compare groups, and the differ-
ences between means and CIs were exponentiated to
provide fold change estimates under the assumption of
perfect probe efficiency.
For a total of 8 miRNAs validated in frontal cortex
and showing the largest fold-change, we also performed
qRT-PCR using cerebellum tissue samples from 10
PGRN+ and 30 PGRN- FTLD-TDP patients, using simi-
lar techniques and analyses, as described above. Indivi-
dual Ct values in the validation data sets for both the
cortex and cerebellum are provided in Additional File 5.
miRNA expression in vitro
SH-SY5Y cells were cultured in a 1:1 mixture of OPTI-
MEM and DMEM containing 5% heat-inactivated FBS
and 1% penicillin/streptomycin. Cell cultures were kept
at 37°C in a humidified atmosphere with 5% CO2. Cells
were seeded at 175, 000 cells/well in 6-well plates and 24
h later transfected with siRNA against PGRN (Qiagen) or
negative control siRNA at a final concentration of 25 nM
using Lipofectamine2000 (Invitrogen). After 48 h of
transfection, total RNA was extracted from SH-SY5Y
cells and quantitative RT-PCR was performed as
described above in the miRNA validation methods
section.
Bioinformatics analysis
It has been extensively reported that miRNAs primarily
decrease mRNA expression and repress translation [38].
For the miRNA candidates significantly dysregulated in
the frontal cortex and cerebellum of PGRN+ FTLD-TDP
patients, we identified their predicted mRNA targets
through TargetScan. For each of those miRNAs, we com-
pared their predicted gene targets with mRNA expression
results of PGRN- and PGRN+ FTLD-TDP patients depos-
ited in the Gene Expression [20] database. The GEO Affy-
metrix array dataset published by Chen-Plotkin et al. (Geo
record GDS3459) profiled mRNA levels in several tissue
types from controls, as well as PGRN+ and PGRN- FTLD
patients [39]. The significantly dysregulated miRNAs
which were anti-correlated in expression with their
mRNA targets in the Affymetrix data set were further ana-
lyzed by Ingenuity software for insight into their biological
roles.
Additional material
Additional file 1: miRNA analysis from PGRN+ and PGRN- FTLD
patients. A table listing all results and statistical analyses from the
miRNA arrays.
Additional file 2: Boxplot profiling of miRNAs in FTLD subtypes. This
file shows comparative boxplots for all 20 significant miRNAs identified in
the miRNA arrays.
Additional file 3: Expression analysis of miRNAs in vitro with PGRN
knockdown. This file shows miRNA expression in human neuroblastoma
SH-SY5Y cells upon siRNA knockdown of PGRN.
Additional file 4: Pathway analysis of mRNA targets for FTLD-
associated miRNAs. This file shows Ingenuity pathway analysis of anti-
correlated mRNA-miRNAs in PGRN+ FTLD-TDP patients.
Additional file 5: qPCR data from miRNA validation studies. A table
listing individual Ct values in the validation data sets for both the cortex
and cerebellum.
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